JA Clinical Reports (Dec 2022)

Anesthetic management with remimazolam in a patient with Child-Pugh C liver cirrhosis: a case report

  • Satoshi Uchida,
  • Daiki Takekawa,
  • Eiji Hashiba,
  • Reiko Kudo,
  • Kazuyoshi Hirota

DOI
https://doi.org/10.1186/s40981-022-00590-9
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Background Remimazolam is a new ultra-short-acting benzodiazepine, and its sedative effect is prolonged in patients with hepatic impairment. This is the first report of remimazolam anesthesia in a patient with Child-Pugh C liver cirrhosis. Case presentation A 52-year-old female was diagnosed with tongue cancer and scheduled for partial glossectomy. Preoperative examinations revealed Child-Pugh C liver cirrhosis, but the pathogenesis was unknown. We scheduled remimazolam anesthesia because it would stabilize her intraoperative circulation. We managed with a much lower-than-normal dose of remimazolam; even so, the patient required flumazenil to regain consciousness. She was admitted to the intensive care unit, but her consciousness remained clear even after the effect of flumazenil had worn off. Conclusion We experienced anesthetic management with remimazolam in a patient with Child-Pugh C liver cirrhosis. Even conservative use of remimazolam in patients with severe hepatic dysfunction may result in emergence times that are delayed longer than expected.

Keywords